17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it
Poolbeg Pharma PLC (AIM:POLB) Poolbeg-led consortium awarded €2.3m in non-dilutive funding to progress Oral Vaccine Platform
Transformative oral vaccine platform funded by the Disruptive Technologies Innovation Fund
Poolbeg Pharma PLC (AIM:POLB) AI programme yields novel RSV drug targets
Artificial intelligence programme yields multiple novel RSV drug targets
Poolbeg Pharma PLC (AIM:POLB) completes in-licence of Melioidosis vaccine candidate
Targeting an infectious disease with a high mortality rate and growing incidence driven by climate change
Poolbeg Pharma (LSE:POLB) Year in (Video) Review 2021
Targeting the growing infectious disease market, we are developing multiple assets quickly to Phase II ready with plans to monetise early to Big Pharma. POLB spun out of Open Orphan
Share Talk catches up with CEO Jeremy Skillington, Poolbeg Pharma (LON: POLB) Interview
Share Talk caught up with our CEO to discuss yesterday’s announcement on #POLB’s has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full
Poolbeg Pharma (POLB.L) agrees terms to develop an oral vaccine delivery platform
16 December, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet,
Women are pushing forward groundbreaking Alzheimer’s treatment ideas that go beyond the headlines
The medical community is now closer than ever to finding treatments for Alzheimer’s disease.
AstraZeneca’s Chronic kidney disease Drug Forxiga approved by European Commission
AstraZeneca’s Forxiga (dapagliflozin), has been approved by the European Commission (EC). It is now available for chronic kidney disease (CKD), in adults with or without type-2 diabetes (T2D), in the
Provexis PLC (PXS.L) Exclusive Distribution Agreement for Chinese CBEC
Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce it has entered into a distribution agreement with a company
Plant Health Care (PHC.L) Update on PHC279 2019 Field Trials
Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update on its completed 2019 field trials of the